The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced...

Area of Science:

• Pharmacology
• Molecular Biology
• Oncology

Background:

• Conventional anticancer therapies often cause significant toxicity to normal tissues, with limited clinical strategies to mitigate these side effects.
• Traditional Chinese Medicine (TCM) extracts show promise in reducing chemotherapy-induced adverse events.
• Identifying novel chemoprotective agents is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To screen traditional Chinese medicine (TCM) compounds for chemoprotective potential against chemotherapy-induced toxicity.
• To identify and characterize the phytochemical Rocaglamide (Roc-A) as a potential chemoprotective agent.
• To elucidate the molecular mechanism underlying Roc-A's chemoprotective effects, particularly its interaction with the p53 pathway.

Main Methods:

• Screening of published cancer-inhibiting TCM compounds.
• Assessment of Roc-A's effect on apoptotic cell death induced by DNA-damaging anticancer drugs in primary human and murine cells.
• Investigation of Roc-A's molecular mechanism, including its impact on p53 protein synthesis, using siRNA knockdown and comparing effects in wild-type and p53-deficient mouse splenocytes.
• Evaluation of Roc-A's efficacy in p53-deficient or -mutated cancer cells.

Main Results:

• Rocaglamide (Roc-A) significantly reduced chemotherapy-induced apoptotic cell death in primary normal cells.
• Roc-A specifically inhibited the DNA damage-induced upregulation of the transcription factor p53 by blocking its protein synthesis.
• The chemoprotective effect of Roc-A was dependent on the presence of functional p53, as it did not protect p53-deficient or -mutated cancer cells.
• siRNA knockdown of p53 and experiments with p53-deficient mice confirmed the essential role of p53 in Roc-A-mediated protection.

Conclusions:

• Rocaglamide (Roc-A) demonstrates significant chemoprotective properties against DNA-damaging anticancer drugs in normal cells.
• The mechanism involves the specific inhibition of p53 protein synthesis, a key mediator of chemotherapy-induced apoptosis.
• Roc-A's efficacy is contingent on functional p53, suggesting its potential as an adjuvant therapy to reduce chemotherapy side effects in patients with p53-deficient or -mutated tumors.